Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study

The safety and efficacy of omalizumab in chronic spontaneous urticaria (CSU) patients has been established, but real-world long-term data remain scarce, especially in Japan. 52-week, open-label, single-arm, observational study evaluated the safety and effectiveness of first-time omalizumab in Japane...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Allergology international 2023-04, Vol.72 (2), p.286-296
Hauptverfasser:	Hide, Michihiro, Fukunaga, Atsushi, Suzuki, Takayuki, Nakamura, Noriko, Kimura, Mine, Sasajima, Takayoshi, Kiriyama, Junna, Igarashi, Atsuyuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Allergic Agents - adverse effects Chronic Disease Chronic spontaneous urticaria Chronic Urticaria - drug therapy Drug-Related Side Effects and Adverse Reactions East Asian People Humans Japan Omalizumab Omalizumab - adverse effects Product Surveillance, Postmarketing Real-world Safety Treatment Outcome Urticaria - chemically induced Urticaria - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The safety and efficacy of omalizumab in chronic spontaneous urticaria (CSU) patients has been established, but real-world long-term data remain scarce, especially in Japan. 52-week, open-label, single-arm, observational study evaluated the safety and effectiveness of first-time omalizumab in Japanese CSU patients responding inadequately to conventional therapies. Overall, 235 of 280 patients completed the study. Most patients were aged ≥ 18 and
ISSN:	1323-8930 1440-1592
DOI:	10.1016/j.alit.2022.09.003